Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
NSE:KOPRAN

KOPRAN LTD

₹275.02
at close · 22 Sept 2026
▼ 8.72 (-3.07%)

Latest filings

  1. BSE seeks clarification from Kopran Ltd on sharp price movement · Regulatory & Legal
  2. Kopran allots 40,500 shares to employees under ESOP 2023 · Capital Market Events
  3. United Shippers (Promoter Group) sells 2.48% in Kopran · Ownership Changes
  4. Kopran clarifies unusual trading volume to NSE query · Regulatory & Legal
  5. NSE queries Kopran on unusual trading volume · Regulatory & Legal
  6. 67th AGM outcome: All 5 resolutions passed, Rs. 3 dividend approved · Board & Shareholder Meetings
  7. Kopran Q1 FY27 results: revenue up but profit down YoY · Compliance
  8. Kopran Q1 FY26-27 Investor Presentation · Investor Communications
  9. Kopran Q1 FY26: Standalone PAT up 91% on 22% revenue growth · Results
  10. Kopran Q1 FY27 Results: Standalone PAT nearly doubles, revenue up 22% · Results
  11. Kopran FY26 Annual Report and 67th AGM notice filed · General
  12. Board meeting on Aug 7, 2026 to consider Q1 FY26-27 results · Results
  13. Kopran: NCLT hearing notice published for Kopran Labs merger · Compliance
  14. Record Date Aug 11, 2026 for Dividend, AGM on Aug 18, 2026 · Corporate Actions
  15. Routine SEBI compliance certificate for Q1 FY26 · Compliance
  16. Routine compliance certificate for Q1 FY27 under SEBI regulation 74(5) · Compliance
  17. Kopran appoints Vijay L Thange as Chief Technical Officer · Management Changes
  18. Trading window closed from July 1 ahead of Q1 results · Compliance
  19. Trading window closed for Kopran Q1 FY27 results · Compliance
  20. Kopran Limited has informed the Exchange Outcome of the Meeting of the Equity Shareholders, Secured Creditors and Unsecured Creditors convened on Wednesday June 03, 2026 · Strategic Transactions
  21. Annual Secretarial Compliance Report for the year ended March 31, 2026 · Compliance
  22. Kopran Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
  23. Newspaper Advertisement for the Q4 Results FY 2025-26 · Compliance
  24. Kopran Limited has informed the Exchange about Investor Presentation · Investor Communications
  25. Investor presentation for 2026. · Investor Communications
  26. Standalone and Consolidated Audited Financial result for the Fourth quarter and Year ended on March 31, 2026. · Results
  27. Kopran Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
  28. Kopran Limited has informed the Exchange about issue of Securities in its subsidiary company · Ownership Changes
  29. Kopran Limited has informed the Exchange regarding Appointment of as Non- Executive Independent Director in its Subsidiary company w.e.f. May 18, 2026. · Management Changes
  30. Appointment of Director & Issue of shares in Subsidiary company Kopran Research laboratories ltd · Fund Raising
  31. Notice of shareholders meeting convened by NCLT to be held on June 03,2026 · Strategic Transactions
  32. Kopran Limited has informed the Exchange about Shareholders meeting · Board & Shareholder Meetings
  33. Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited .... · Results
  34. Kopran Limited has informed the Exchange about Copy of Newspaper Publication pursuant to the directions of NCLT, Mumbai Bench, vide Order dated April 09, 2026, for Notice served to the members, secured creditors and unsecured creditors for approval of Scheme of Amalgamation · Compliance
  35. Newspaper Advertisement pursuant to NCLT Order dated April 09, 2026 Mumbai Bench, for Notice served to the members, creditors, for the approval of Scheme of Amalgamation. · Compliance
  36. Kopran Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on Jun 03, 2026 · Strategic Transactions
  37. Kopran Limited has informed the Exchange about Amalgamation/Merger · Strategic Transactions
  38. Kopran Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
  39. Kopran Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
  40. Kopran Limited has informed the Exchange about Amalgamation/Merger · Strategic Transactions
  41. Significant movement in price has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Kopran Limited has submitted their response. · Compliance
  42. NSE seeks clarification from Kopran on unusual price movement · Compliance
  43. Kopran Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
  44. Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Kopran Limited has submitted their response. · Compliance
  45. Significant increase in volume has been observed in Kopran Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · General
  46. Kopran Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
  47. Kopran Limited has informed the Exchange regarding Resignation of Mr. Adarsh Somani as Non- Executive Director of the company w.e.f. March 17, 2026. · Management Changes
  48. Kopran Limited has informed the Exchange about Amalgamation/Merger · Strategic Transactions
  49. Kopran Limited has informed the Exchange about Observation Letter received from BSE Limited on the Scheme of Amalgamation. · Strategic Transactions
  50. Kopran Limited has informed the Exchange about Cyber-attack at khopoli Factory · Capex & Operations
All filings ↓
Ask Nexa about KOPRAN LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Operates as an integrated pharmaceutical company with two main businesses: Active Pharmaceutical Ingredients (APIs) manufactured through subsidiary Kopran Research Laboratories Limited (KRLL), and Formulations. The group sells APIs and formulations across more than 50 countries, with exports a major part of the revenue base. In FY26, consolidated revenue was ₹68,142 lakhs, Q4 FY26 revenue reached ₹23,402 lakhs (up 36% year-on-year and the highest ever quarterly figure), and Q4 EBITDA was ₹4,057 lakhs at a 17.34% margin. Materials accounted for 63.3% of revenue, making raw material sourcing — including an explicit strategy to reduce China dependence for APIs — the principal cost lever. A scheme of amalgamation to absorb Kopran Laboratories into the parent is in progress (NCLT-admitted), and the API subsidiary is raising ₹18.75 crore via a rights issue for working capital. Planned capacity additions include a new API and R&D facility at Panoli, Gujarat, and automation of formulations packing lines. Full-year FY26 net profit fell to ₹2,573 lakhs from ₹3,855 lakhs in FY25, weighed down by ₹1,595 lakhs of foreign exchange losses.

Operating scale
Export markets
50+ countriesFY26
FY26 consolidated revenue
Rs 68,142 lakhsFY26
Q4 FY26 revenue
Rs 23,402 lakhs (highest ever quarterly, up 36% YoY)Q4 FY26
Q4 FY26 EBITDA
Rs 4,057 lakhs at 17.34% marginQ4 FY26
FY26 forex losses
Rs 1,595 lakhsFY26
Planned API/R&D facility
Panoli, Gujarat (capacity expansion planned)
Who pays it
Pharma buyers in more than 50 countries, served through exports of APIs and formulations.
Biggest cost
Materials at 63.3% of revenue, including API intermediates where the company is working to reduce China dependence.
Kind of business
Integrated, export-oriented pharmaceutical manufacturer across APIs and Formulations, with material costs as the dominant input.
Where it sits
Vertically integrated pharma player with API manufacturing through KRLL and a formulations business selling in 50+ countries; currently merging KRLL into the parent.
Market Cap
₹1,328 Cr
P / E (TTM)
53.2×
EV / EBITDA
23.3×
Div Yield
1.09%
Growth
6.7%▲
Revenue 5y CAGR
PAT -16.0% · EBITDA -9.0%
Quality
10.4%·
ROCE (5y median)
ROE 7.4% · margin 9.1%
Leverage
0.29·
Debt / Equity · low
Net debt ₹152 Cr
Revenue FY21→FY26
1.4×▲
Margin −8.8 pts
₹492 Cr → ₹681 Cr
Cash conversion
0.75×·
Operating cash ÷ profit · 5 yrs
₹152 Cr on ₹204 Cr
Moves on a normal day
1.67%·
Median daily move
Last 268 sessions · filing days run larger

Scorecard

Measured from the filed financials · as of FY26 — not investment advice

Strengths
Debt at 0.29× equity
Pays out 56% of profit as dividend
Concerns
Profit shrinking over 5 years (-16% a year)
Erratic profits — up in only 1 of the last 5 years
Heavy working capital — 144 days of cash tied up
Customers are taking longer to pay — 89 → 141 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from KOPRAN LTD's filed financials and exchange disclosures

What does KOPRAN LTD do?

KOPRAN LTD is listed on NSE and BSE, trading under the symbol KOPRAN.

Is KOPRAN LTD profitable?

Yes. Over the trailing twelve months KOPRAN LTD reported a net profit of ₹25 Cr on revenue of ₹700 Cr.

Does KOPRAN LTD pay a dividend?

Yes. The dividend yield is 1.09% at the current price. It paid out 56% of its profit as dividend in FY26.

Is KOPRAN LTD debt-free?

No. Debt stands at 0.29× equity, and it carries net debt of ₹152 Cr.

How much does the KOPRAN LTD share price move in a day?

On a typical session KOPRAN LTD moves 1.67% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.

Where can I track KOPRAN LTD's announcements?

Every NSE and BSE filing by KOPRAN LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.